Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme

• Published in: Cancer control 2022-09, Vol.29, p.10732748221131000-10732748221131000
• Main Authors: Martínez, M. T., Moragon, S., Ortega-Morillo, B., Montón-Bueno, J., Simon, S., Roselló, S., Insa, A., Viala, A., Navarro, J., Sanmartín, A., Fluixá, C., Julve, A., Soriano, D., Buch, E., Peña, A., Franco, J., Martínez-Jabaloyas, J., Marco, J., Forner, M. J., Cano, A., Silvestre, A., Teruel, A, Bermejo, B., Cervantes, A., Chirivella Gonzalez, I.
• Format: Article
• Language: English
• Subjects: Cancer; Coronaviruses; COVID-19; Diagnosis; Lung cancer; Medical diagnosis; Original; Pandemics; Patients; Primary care; Public health
• ISSN: 1073-2748; 1526-2359
• DOI: 10.1177/10732748221131000

Introduction The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public health concerns that possible delays could increase the proportion of patients diagnosed at advanced stages. In 2009, a cancer fast-track program (CFP) was implemented at the Clinico-Malvarrosa Health Department in Valencia, Spain with the aim of shortening waiting times between suspected cancer symptoms, diagnosis and therapy initiation. Objectives The study aimed to explore the effects of the COVID-19 pandemic on our cancer diagnosis fast-track program. Methods The program workflow (patients included and time periods) was analysed from the beginning of the state of alarm on March 16th, 2020 until March 15th, 2021. Data was compared with data from the same period of time from the year before (2019). Results During the pandemic year, 975 suspected cancer cases were submitted to the CFP. The number of submissions only decreased during times of highest COVID-19 incidence and stricter lockdown, and overall, referrals were slightly higher than in the previous 2 years. Cancer diagnosis was confirmed in 197 (24.1%) cases, among which 33% were urological, 23% breast, 16% gastrointestinal and 9% lung cancer. The median time from referral to specialist appointment was 13 days and diagnosis was reached at a median of 18 days. In confirmed cancer cases, treatment was started at around 30 days from time of diagnosis. In total, 61% of cancer disease was detected at early stage, 20% at locally advanced stage, and 19% at advanced stage, displaying time frames and case proportions similar to pre-pandemic years. Conclusions Our program has been able to maintain normal flow and efficacy despite the challenges of the current pandemic, and has proven a reliable tool to help primary care physicians referring suspected cancer patients.